stockrowGeoVax Labs Inc.
GOVX Healthcare Biotechnology
GeoVax Labs Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 million, down 37.1% from fiscal 2024.
- Revenue
- +183.4%
- EPS
- +88.9%
- Free cash flow
- +15.8%
Quarter to June 2026, against a year earlier
Follow GOVX
Alert me
GeoVax Labs Inc. (GOVX) EV/Sales
As of 6 November 2026, GeoVax Labs Inc. (GOVX) trades at a EV/Sales of −0.3×. Over the past ten years it has ranged from −62.8× (July 2022) to 91,084,096,922× (October 2015); the current reading is higher than 21% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.2× | (87.56%) |
| FY2024 | 1.9× | — |
| FY2022 | −46.2× | — |
| FY2021 | 28.9× | — |
| FY2020 | −2.6× | — |
| FY2019 | −0.2× | — |
| FY2018 | −0.2× | — |
| FY2017 | 37,008,444,940× | 19.18% |
| FY2016 | 31,053,854,505× | (42.21%) |
| FY2015 | 53,736,790,467× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2025 | 1.7× | 70.64% |
| Mar 2025 | 1.0× | (46.95%) |
| Dec 2024 | 1.9× | (12.43%) |
| Sep 2024 | 2.2× | (82.51%) |
| 30 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| GOVX GeoVax Labs Inc. | −0.3× |
| CARM Carisma Therapeutics Inc. compare | 0.0× |
| GNPX GENPREX compare | n/m |
| PPCB Propanc Biopharma Inc compare | n/m |
| XRTX XORTX Therapeutics Inc. compare | n/m |
| KAPA Kairos Pharma, Ltd. compare | n/m |
| VRAX Virax Biolabs Group Limited compare | n/m |
| OGEN Oragenics, Inc. compare | 0.7× |
| ITRMF Iterum Therapeutics PLC compare | 24.4× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)